102 results
F-3
ACIU
AC Immune SA
14 Mar 24
Shelf registration (foreign)
4:43pm
and a-syn-PET tracer ACI-12589) and to a lesser extent our preclinical candidates;
the preclinical and clinical safety, efficacy and utility of our
6-K
EX-99.1
ACIU
AC Immune SA
14 Mar 24
Current report (foreign)
7:44am
is advancing through Phase 2 testing for Parkinson’s disease (PD) with initial safety and immunogenicity data expected in the second half of 2024.
“AC Immune’s … expanded. Following data safety monitoring board (DSMB) review, no safety concerns have been raised to date, consistent with the previously observed
6-K
EX-99.1
ACIU
AC Immune SA
22 Jan 24
Current report (foreign)
7:53am
in a lower incidence of side effects known as ARIA (Amyloid-Related Imaging Abnormalities). The investigational medicine has demonstrated excellent safety (e.g
6-K
EX-99.1
ACIU
AC Immune SA
3 Jan 24
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson's diseases
4:19pm
VacSYn Phase 2 PD trial of ACI-7104.056 completed enrollment of cohort 1 and commenced cohort 2; safety and immunogenicity update expected in H2 2024 … ) continues fully blinded, with cohorts 1 and 2 enrolled and cohort 3 enrollment to be completed in January. Following data safety monitoring board (DSMB
424B5
9jybn2oaw9p29k
15 Dec 23
Prospectus supplement for primary offering
5:27pm
6-K
EX-99.1
kwvnn9q
15 Dec 23
Current report (foreign)
7:27am
6-K
EX-99.2
64fo53 2oqmi
3 Nov 23
Current report (foreign)
7:30am
6-K
EX-99.3
mhebiizni 1km
3 Nov 23
Current report (foreign)
7:30am
6-K
EX-99.3
x3z9muk6nbq0tr
4 Aug 23
Current report (foreign)
7:30am
6-K
EX-99.2
m38v 007d
4 Aug 23
Current report (foreign)
7:30am
6-K
EX-99.1
xzmr2 k17l8u
27 Jun 23
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
8:22am
6-K
sxpyolhtcpf9ok5u8 rw
27 Jun 23
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
8:22am
6-K
EX-99.1
nywe805ue
26 Jun 23
Current report (foreign)
8:40am
6-K
EX-99.2
qlgt2xg8z
26 Jun 23
Current report (foreign)
8:40am
6-K
EX-99.1
4jpxavhqy2k p3nf3r3y
24 May 23
Invitation to the Annual General Meeting 2023 To the Shareholders of AC Immune SA
4:07pm
6-K
EX-99.2
x13mt3o02o64t4lz
28 Apr 23
Current report (foreign)
7:30am
6-K
EX-99.3
0zvcr2i6
28 Apr 23
Current report (foreign)
7:30am
6-K
EX-99.2
s2n2 kq03qsqt1se3e
28 Oct 22
Current report (foreign)
8:00am
6-K
EX-99.3
2ntxiwz gk
28 Oct 22
Current report (foreign)
8:00am